Immix Biopharma (IMMX) Other financing activities (2021 - 2026)

Immix Biopharma has reported Other financing activities for 5 years, with the latest figure at $33532.0 in Q1 2026.

• Quarterly Other financing activities changed N/A year-over-year to $33532.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $34050.0 (changed N/A YoY) and the FY2025 annual result came in at $6342.0, up 154.8% from the prior year.
• Other financing activities climbed to $33532.0 in Q1 2026 per IMMX's latest filing, from $2.0 in the prior quarter.
• Over five years, Other financing activities peaked at $175000.0 in Q1 2023 and troughed at -$172382.0 in Q4 2023.
• A 4-year average of $6526.2 and a median of $1502.5 in 2024 frame the typical range for Other financing activities.
• The widest YoY moves for Other financing activities: up 98.58% in 2024, down 98.58% in 2024.
• Over 4 years, Other financing activities stood at -$172382.0 in 2023, then soared by 101.44% to $2489.0 in 2024, then plunged by 99.92% to $2.0 in 2025, then surged by 1676500.0% to $33532.0 in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered $33532.0, $2.0, and $516.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.